Khaberni - A research team found that taking the drug Eluramylintide once a week leads to weight loss, up to 20% over 48 weeks for those with obesity or overweight who do not have type 2 diabetes.
The study trials were conducted at 46 centers in the United States, involving 263 individuals aged between 18 and 75 years, with an average age of 49 years.
According to "Medical Xpress", participants received weekly subcutaneous injections of Eluramylintide, along with identical placebo injections. The drug treatment was accompanied by consultations on lifestyle and diet.
How the injection works
Eluramylintide injections act as a selective agonist for amylin receptors which are secreted along with insulin in response to nutrients, slow stomach emptying, reduce glucagon levels, and help in feeling full.
All Eluramylintide groups showed a reduction in body weight compared to the placebo treatment after 48 weeks.
Weight Reduction by Dosage
The average percentage change in body weight was -9% at 1 mg dose, -12% at 3 mg dose, -18% at 6 mg dose, and -20% at 9 mg dose.
The dose groups reaching or equivalent to 9 mg had the greatest effect, with an average weight change of -21.3 kg. Waist circumference decreased by up to 17.1 cm.
The trials were conducted under the supervision of Endeavor Health and Eli Lilly Pharmaceuticals.
